AUG 13·SEC EDGARLow
Monroe Terilyn J. sold $7.6M of GH
Monroe Terilyn J. (Chief People Officer) sold 46,300 shares of Guardant Health, Inc. (GH) at an average of $165.12 ($163.41–$167.92, $7.65M total) across 5 trades on 2026-08-12.
StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$GH
Guardant Health, Inc.
Price · $GHvia TradingView
AI sentiment · 7d3 articles
- Bullish
- 1
- Neutral
- 2
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $21.0M 14 txs
Monroe Terilyn J.5× · $7.6M
10b5-1 share of filings7%
Top stories · $GHMore →
AUG 12·yahoo.com
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million
Guardant Health (NASDAQ:GH) director Ian T. Clark sold 14,180 shares indirectly on Aug. 4, 2026 via an exercise-and-sell of options with a $50.57 strike, for about $2.3 million, at a weighted average price of $158.92. After the sale, indirect holdings fell to 2,975 shares. Guardant reported TTM revenue of $1.2 billion and a net loss of $453.4 million.
AUG 11·SEC EDGAR
Freeman Chris sold $10.8M of GH
Freeman Chris (Chief Commercial Officer) sold 63,605 shares of Guardant Health, Inc. (GH) at an average of $169.58 ($167.38–$170.24, $10.79M total) across 4 trades on 2026-08-10.
GH sentiment & insider activity
Over the past 7 days, alphai's AI scored 3 news stories mentioning GH (Guardant Health, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent GH coverage spans insider activity, earnings and financial news.
In the last 30 days, GH insiders filed 14 SEC Form 4 transactions — no purchases and 14 sales ($21.0M). The most active reporter was Monroe Terilyn J., Chief People Officer, with 5 filings. 7% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving GH
The filing is a routine insider sale with no 10b5-1 plan disclosed, but it does not provide new operational or financial information.
The filing is a routine insider disposal with no stated operational or guidance change, so near-term price impact is likely limited.
This is a large insider open-market sale by the Chief Commercial Officer, but it is not tied to a 10b5-1 plan in the filing.
Higher guidance and a financing shelf can support upside, but the wider net loss and ongoing cash burn risk keep valuation fragile.
Raised guidance and detailed Shield cost-per-test targets and reimbursement progress, supporting a constructive near-term earnings and margin narrative.
alphai scores every news story that mentions GH with an AI model for sentiment and relevance, and aggregates insider trades from Guardant Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $GH
Score
Monroe Terilyn J. sold $7.6M of GH
Monroe Terilyn J. (Chief People Officer) sold 46,300 shares of Guardant Health, Inc. (GH) at an average of $165.12 ($163.41–$167.92, $7.65M total) across 5 trades on 2026-08-12.
1 min read
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million
Guardant Health (NASDAQ:GH) director Ian T. Clark sold 14,180 shares indirectly on Aug. 4, 2026 via an exercise-and-sell of options with a $50.57 strike, for about $2.3 million, at a weighted average price of $158.92. After the sale, indirect holdings fell to 2,975 shares. Guardant reported TTM revenue of $1.2 billion and a net loss of $453.4 million.
3 min readFreeman Chris sold $10.8M of GH
Freeman Chris (Chief Commercial Officer) sold 63,605 shares of Guardant Health, Inc. (GH) at an average of $169.58 ($167.38–$170.24, $10.79M total) across 4 trades on 2026-08-10.
2 min readGuardant Health (GH) Following Earnings And Higher Guidance Has Valuation Back In Focus
Simply Wall St reports Guardant Health (GH) released Q2 2026 results with a wider net loss but higher sales, raised full-year revenue guidance, and filed a shelf registration for multiple securities. The article cites GH’s stock moves after the release and discusses a fair value estimate near $171.08 versus a $168.48 close, plus valuation multiples and risks.
6 min read
Guardant Health (GH) Q2 2026 Earnings Call Transcript
Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.
7 min readHidalgo Medina Manuel sold $279K of GH
Hidalgo Medina Manuel sold 1,700 shares of Guardant Health, Inc. (GH) at an average of $164.24 ($163.94–$164.61, $0.28M total) across 2 trades on 2026-08-05.
1 min readCLARK IAN T sold $2.3M of GH (indirect holdings)
CLARK IAN T sold 14,180 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $158.92 ($158.80–$158.98, $2.25M total) across 2 trades on 2026-08-04.
2 min read
New blood test to detect colon cancer clears FDA approval
The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.
6 min readBTIG Names Top Healthcare Stock Pick Led by Guardant Health
BTIG named Guardant Health its top healthcare pick after strong Q2 results. BTIG kept a Buy rating and raised its price target to $195 from $190. Guardant reported Q2 revenue of $335 million, up 44%, and 63% core oncology volume growth, and raised full-year guidance. Catalysts cited include potential CMS coverage for Reveal MRD and launches of Reveal Ultra MRD in 2H 2026 and G360 ADLT status in 1H 2027.
4 min readGuardant Health, Inc. Q2 2026 Earnings Call Summary
Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.
6 min read